Harish Shantharam
Known title: Chief Financial OfficerCIK: 0001976391
Harish Shantharam's purchase track record
Harish Shantharam has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/18/2025 | ALXO | $58K | +60.7% | +133.8% | +6.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALXO | ▲ Buy | Open Market | 75,000 | $58K | 8/18/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
ALX Oncology reports positive Phase 2 data for evorpacept
ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.
ALX Oncology reports positive Phase 2 data for evorpacept. ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.